|Bid||17.050 x 1300|
|Ask||17.050 x 1400|
|Day's Range||16.700 - 17.200|
|52 Week Range||9.550 - 20.869|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Teva Pharmaceutical Industries (TEVA) received FDA approval for its Ajovy (fremanezumab-vfrm) injectable on September 14. The chart below shows the company’s quarterly sales trend. The marketing application for Ajovy was filed by Teva in Europe in February. Teva’s (TEVA) Ajovy is an anti-CGRP (calcitonin gene-related peptide) migraine prevention treatment and offers monthly and quarterly dosage options.
Biotech plays are numerous, and Morgan Stanley has a few recommendations to pare and prop a pharma portfolio. The Ratings Analyst Jeffrey Hung initiated coverage of: Alder Biopharmaceuticals Inc (NASDAQ: ...
Until recently, there was no specific treatment for migraine, although symptom-alleviating options such as beta blockers, antidepressants and even Botox were invariably used by affected individuals. Aimovig, a preventative treatment option for migraines, belongs to a class of drugs called calcitonin gene-related peptide — or CGRP — inhibitors and antagonists.
On a per-share basis, the Bothell, Washington-based company said it had a loss of $1.04. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Alder Biopharmaceuticals, the Puget Sound region's third-largest biotech, has lost two of its three founders in the last six months and hired new leaders.
Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR ) is set to release its second-quarter earnings report after the bell Tuesday, and Stifel reviewed the stock ahead of the print. The Analysts Stifel analyst ...
Short interest is high for ALDR with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting ALDR. The net inflows of $2.00 billion over the last one-month into ETFs that hold ALDR are not among the highest of the last year and have been slowing.
Investors in Alder Biopharmaceuticals (ALDR) need to pay close attention to the stock based on moves in the options market lately.
Short interest is moderately high for ALDR with between 10 and 15% of shares outstanding currently on loan. Over the last month, growth of ETFs holding ALDR is favorable, with net inflows of $5.46 billion.
Alder Biopharmaceuticals gapped up Friday after rival Teva Pharmaceutical scrapped a late-stage study in chronic cluster headaches.
The hire could fuel rumors that Alder is searching for a buyer at the same time the Bothell-based company is seeking Food and Drug Administration approval for its flagship migraine drug, eptinezumab.
Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.
Alder Biopharmaceuticals likely will seek a buyer, an analyst said Thursday as shares tanked on the hire of a new chief executive.
On May 23, Teva Pharmaceutical Industries (TEVA) announced that the FDA has confirmed the PDUFA date for its migraine drug Fremanezumab as September 16, 2018, against the previously provided date of June 16. The approval was delayed due to an FDA warning received by Teva’s partner Celltrion in February. Guggenheim analyst Rohit Vanjani believes the FDA approval delay could prove to be positive ultimately if the re-inspection at the Celltrion facility is completed without any further issues.
Migraine is one of the top 10 causes of years lived with disability globally. With Aimovig receiving FDA approval for treatment of migraine, investors' attention is on future regulatory decisions.